Novartis is currently the only company providing a treatment for advanced prostate cancer that is in short supply.

Key Highlights :

1. Pluvicto is in short supply, and the FDA has issued a letter outlining the reasons behind the shortage.

2. Novartis is currently prioritizing patients who have already received doses of the drug and are currently in the treatment process.

3. The company is seeking FDA approval for manufacturing commercial Pluvicto at its site in Millburn, New Jersey. If this approval is granted, the company will be able to increase its supply of the drug.

Trying to live a healthy lifestyle while battling cancer.

Continue Reading at Source : cbsnews